Medicis Pharmaceutical Corp. (MRX) is in the Pharma Industry

• Sort by

• Medicis Pharmaceutical Corporation Q1 2008 Earnings Call Transcript

  Medicis Pharmaceutical Corporation Q1 2008 Earnings Call Transcript

  Earnings calls 2008-05-30

  Tags: Medicis Pharmaceutical Corp., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Medicis Pharmaceutical Corp. Q4 2007 Earnings Call Transcript

  Medicis Pharmaceutical Corp. Q4 2007 Earnings Call Transcript

  Earnings calls 2008-03-10

  Tags: Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance, Medicis Pharmaceutical Corp.

Additional Resources

• Collagen Wrinkle Filler Approved

  The U.S. Food and Drug Administration has approved Evolence to treat moderate-to-severe facial wrinkles and folds, maker Johnson & Johnson said Wednesday. The injected treatment is made from "naturally sourced collagen" using tendons harvested from pigs in the United States and Australia, The Wall Street Journal quoted the company...

  Articles 2008-07-03

• Perrigo Confirms Filing for Generic Version of VANOS®

  ALLEGAN, Mich., June 9 /PRNewswire-FirstCall/ -- Perrigo Company today announced that it has filed an Abbreviated New Drug Application ANDA for Fluocinonide Cream 0.1%, a generic version of VANOSR Cream 0.1%. The Company believes that it is the first to file an ANDA with a Paragraph...

  Articles 2008-06-09

• Revance Announces Series C Expansion

  MOUNTAIN VIEW, Calif. -- Revance Therapeutics, Inc. ("Revance") today announced the completion of an additional $8 million investment to the Series C financing that was completed in December 2007. The expansion led by Bio*One Capital brings the total Series C to $51.2 million. The financing included returning investors, Essex Woodlands...

  Articles 2008-05-12

• Progressive Following on Medicis Pharmaceutical Corporation.

  M2 PRESSWIRE-28 February 2008-Street Tips: Progressive Following on Medicis Pharmaceutical CorporationC1994-2008 M2 COMMUNICATIONS LTD RDATE:28022008 Streetinvesting.com has now resumed our progressive review of Medicis Pharmaceutical Corporation (NYSE:MRX) after it traded up 8% Thursday, early in the morning, with below-average...

  Articles 2008-02-28

• IMPAX Announces Lawsuit Related to Generic Version of SOLODYN®

  HAYWARD, Calif. -- IMPAX Laboratories, Inc. (OTC:IPXL) today announced that it has filed a lawsuit against Medicis Pharmaceutical Corporation in the United States District Court for the Northern District of California requesting a declaration that IMPAX does not infringe any valid claims of U.S. Patent No. 5,908,838 related to IMPAX's...

  Articles 2008-01-15

• Allergan's Botox May Have a Cheaper Rival in Reloxin

  Avanir Focusing on Zenvia Drug; UCI Scientist Gets $2M to Study Stem Cells, Heart Disease HEALTHCARE For nearly two decades Allergan Inc., the Irvine drug maker, has had a monopoly on the anti-wrinkle market through its billion-dollar flagship Botox. That could be about to change....

  Articles 2007-12-31

• Ipsen and Medicis Announce Submission of Reloxin® in Aesthetics to the FDA

  PARIS & SCOTTSDALE, Ariz. -- Regulatory News: Ipsen (Paris:IPN) and Medicis (NYSE:MRX) today announced the submission of the Biologics License Application ("BLA") for Reloxin([R]1) to the U.S. Food and Drug Administration ("FDA"). Upon FDA's acceptance of the Reloxin([R])filing, Medicis will pay Ipsen approximately $25 million...

  Articles 2007-12-06

• NEA Participates in $40M Investment in Hyperion Therapeutics

  Demonstrates Continued Commitment to Outstanding Teams and Products MENLO PARK, Calif. -- New Enterprise Associates NEA has invested in South San Francisco, CA-based Hyperion Therapeutics, a biopharmaceutical company focused on the development and commercialization of gastrointestinal and hepatology therapies for the treatment of Urea Cycle...

  Articles 2007-09-05

• InNexus Appoints FDA Expert Dr. Jur Strobos to Chief Medical Officer

  BRITISH COLUMBIA, Canada -- InNexus Biotechnology Inc. (OTCBB: IXSBF, TSX VENTURE: IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL[TM]) technology, has appointed Dr. Jur Strobos to Chief Medical Officer. Dr. Jur Strobos brings with...

  Articles 2007-08-01

• BioSante Pharmaceuticals Announces Positive Results for its CaP Technology for Use in Aesthetic Medicine

  LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced positive results of the use of BioSante's calcium phosphate nanotechnology CaP as a potential wrinkle filler in cosmetic medicine. These results are based on work performed by Medical Aesthetics Technology Corporation ("MATC") with whom BioSante has entered...

  Articles 2007-07-25

• New Report Gives Forecasts to 2010 for the Global Botulinum Toxin Market

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c62936) has announced the addition of Botulinum Toxin - Global Strategic Business Report to their offering. This report analyzes the worldwide markets for Botulinum Toxin in Millions of US$. The end-use segments analyzed are Cosmetic Applications, and Therapeutic Applications....

  Articles 2007-07-17

• Seno Medical Instruments, Inc. Selects Dr. John Holaday to Scientific Advisory Committee

  SAN ANTONIO -- Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices, announces the selection of John Holaday, PhD, to its Scientific Advisory Committee. Dr. Holaday, formerly listed among the 500 most cited scientists in the world by the Science Citation...

  Articles 2007-06-12

• EXECUTIVE SUMMARY

  This post week's news from www.ocbj.com and other sources TECHNOLOGY Amp'd Mobile Inc. has filed for bankruptcy, capping a spectacular rise for the edgy wireless phone company started in Orange County. The company got its start in AHso Viejo before moving to Los Angeles in 2005. Founder and...

  Articles 2007-06-11

• Combination Products Are a Lifeline in Today's Pharmaceutical Industry, but Not All Are Created Equal

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c59188) has announced the addition of the new Decision Resources "SPECIAL REPORT: Getting Maximum Benefit from Combination Products" to their offering. Combination products are a lifeline in today's pharmaceutical industry, but not all are created equal. Many companies use...

  Articles 2007-06-08

• Medicis settles with feds.(Policy & Practice)

  Medicis Pharmaceutical Corp. of Scottsdale, Ariz. has agreed to pay the U.S. government $9.8 million to settle allegations that it illegally promoted Loprox ciclopirox as a diaper rash treatment. Loprox is not approved by the Food and Drug Administration for skin disorders in children under age...

  Articles 2007-06-01

• Medicis Pharmaceutical to Pay U.S. $9.8 Million to Resolve False Claims Allegations

  To: MEDICAL EDITORS Contact: Office of U.S. Department of Justice, +1-202-514-2007,TDD: +1-202-514-1888 WASHINGTON, May 8 /PRNewswire-USNewswire/ -- MedicisPharmaceutical Corporation of Scottsdale, Ariz., will pay the UnitedStates $9.8 million to settle allegations that the company violatedthe False Claims Act with respect to claims submitted to Medicaid,the Justice Department announced today....

  Articles 2007-05-08

• Market Commentary on Medicis Pharmaceutical Corp.

  M2 PRESSWIRE-4 May 2007-Biotech News: Market Commentary on Medicis Pharmaceutical CorpC1994-2007 M2 COMMUNICATIONS LTD RDATE:04052007 Market Commentary on Medicis Pharmaceutical Corp (NYSE:MRX) Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment...

  Articles 2007-05-04

• Combination gel for acne vulgaris.(Products)

  Ziana (clindamycin phosphate 1.2% and tretinoin 0.025%) gel is now available for once-daily topical treatment of ache vulgaris in children who are 12 years of age or older. The gel has an alcohol-free aqueous base. The manufacturer expects to begin shipping the product to wholesalers in...

  Articles 2007-05-01